Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clindamycin phosphate, quantity: 714 mg (equivalent: clindamycin, qty 600 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; disodium edetate - clindamycin viatris is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin viatris is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clindamycin phosphate, quantity: 357 mg (equivalent: clindamycin, qty 300 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; disodium edetate - clindamycin viatris is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin viatris is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate.

Israel - English - Ministry of Health

rafa laboratories ltd - clindamycin as phosphate - solution for injection - clindamycin as phosphate 150 mg/ml - clindamycin - clindamycin - the treatment of infections caused by susceptible anaerobic bacteria.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - clindamycin hydrochloride, quantity: 162.87 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; purified talc; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate; carmoisine; patent blue v - clindamycin bnm (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin bnm capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. ,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. ,anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. ,streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. ,staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. ,pneumococci serious respiratory tract infections. ,adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. ,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - tretinoin, quantity: 0.25 mg; clindamycin phosphate, quantity: 12 mg (equivalent: clindamycin, qty 10 mg) - gel - excipient ingredients: purified water; disodium edetate; methyl hydroxybenzoate; carbomer 981; butylated hydroxytoluene; polysorbate 80; citric acid; glycerol; propyl hydroxybenzoate; trometamol - acnatac is indicated for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older. consideration should be given to official guidance on the appropriate use of antibacterial agents and acne treatment.

United States - English - NLM (National Library of Medicine)

sandoz inc - clindamycin (unii: 3u02el437c) (clindamycin - unii:3u02el437c) - clindamycin 6 mg in 1 ml - clindamycin in 5% dextrose injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin in 5% dextrose injection is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of antibiotic-associated pseudomembranous colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. indicated surgical procedures should be performed in conjunction with antibiotic therapy. clindamycin in 5% dextrose injection is indicated in the treatment of serious infections caused b

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin 10 mg in 1 ml - clindamycin phosphate topical solution, usp 1% is indicated in the treatment of acne vulgaris. in view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (see contraindications, warnings and adverse reactions ). clindamycin phosphate topical solution is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis. safety and effectiveness in pediatric patients under the age of 12 have not been established. clinical studies for clindamycin phosphate topical solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

United States - English - NLM (National Library of Medicine)

sandoz inc - clindamycin (unii: 3u02el437c) (clindamycin - unii:3u02el437c) - clindamycin 6 mg in 1 ml - clindamycin in 5% dextrose injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin in 5% dextrose injection is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of antibiotic-associated pseudomembranous colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. indicated surgical procedures should be performed in conjunction with antibiotic therapy. clindamycin in 5% dextrose injection is indicated in the treatment of serious infections caused b

Canada - English - Health Canada

taro pharmaceuticals inc - clindamycin (clindamycin phosphate) - solution - 1% - clindamycin (clindamycin phosphate) 1% - antibiotics

Canada - English - Health Canada

fresenius kabi canada ltd - clindamycin (clindamycin phosphate) - solution - 150mg - clindamycin (clindamycin phosphate) 150mg - lincomycins